Clinical Trial of Growth Factor Therapy for Patients with End-stage Dilated Cardiomyopathy on Heart Transplantation List

2005 ◽  
Vol 11 (9) ◽  
pp. S264
Author(s):  
Kazuo Komamura ◽  
Akihisa Hanatani ◽  
Masakazu Yamagishi ◽  
Akiko Mano ◽  
Takeshi Nakatani ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Growth Factor ◽  
Heart Transplantation ◽  
Dilated Cardiomyopathy ◽  
Factor Therapy ◽  
End Stage ◽  
Growth Factor Therapy

Clinical trial of regeneration of aged vocal folds with growth factor therapy

2012 ◽  
Vol 122 (2) ◽  
pp. 327-331 ◽  
Author(s):  
Shigeru Hirano ◽  
Ichiro Tateya ◽  
Yo Kishimoto ◽  
Shin-ichi Kanemaru ◽  
Juichi Ito
Keyword(s):  
Clinical Trial ◽  
Growth Factor ◽  
Vocal Folds ◽  
Factor Therapy ◽  
Growth Factor Therapy

Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules

2007 ◽  
Vol 5 (2) ◽  
pp. 229-234
Author(s):  
Betsy L. Althaus
Keyword(s):  
Clinical Trial ◽  
Growth Factors ◽  
Growth Factor ◽  
Febrile Neutropenia ◽  
Dose Delivery ◽  
Factor Therapy ◽  
Clinical Trial Results ◽  
Growth Factor Therapy ◽  
Prescribing Information ◽  
The U.S

Myeloid growth factors (MGFs) are used for the prophylaxis of febrile neutropenia and maintenance of scheduled dose delivery in the treatment of patients undergoing cancer chemotherapy. To spare cost and for patient convenience, in adults MGFs are used at schedules, doses, and durations that differ from the approved prescribing information of the U.S. Food and Drug Administration. These variations include rounding doses to convenient sizes, fewer days of treatment, a shorter interval between cycles, and same-day administration with chemotherapy. Some of these variations are supported by clinical trial results and practice guidelines.

scholarly journals Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Bo Zhao ◽  
Laura S. Wood ◽  
Karen James ◽  
Brian I. Rini
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cardiac Ischemia ◽  
Vascular Endothelial ◽  
Cardiac Events ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia.

Sign in / Sign up

Export Citation Format

Share Document